Author(s): Fung CY, Tarbell NJ, Lucarelli MJ, Goldberg SI, Linggood RM, et al.
Purpose:To evaluate the clinical behavior and treatment outcome of ocular adnexal lymphomas classified by the World Health Organization system, with emphasis on marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT).
Materials and methods:The clinicopathologic materials from 98 consecutive patients treated for ocular adnexal lymphoma were reviewed. Fourteen patients had prior lymphoma and 84 patients had primary disease (75% Stage I, 6% Stage III, and 19% Stage IV). Radiation (photons/electrons) was administered to 102 eyes to a median dose of 30.6 Gy. The mean follow-up was 82 months.
Results:The most common subtypes among the primary patients were MALT (57%) and follicular (18%) lymphoma. The 5-year actuarial local control rate in 102 irradiated eyes was 98%. Among the low-grade lymphomas, the 5-year local control rate correlated with the radiation dose in the MALT lymphoma subgroup (n = 53): 81% for <30 Gy and 100% for > or =30 Gy (p <0.01). For the non-MALT low-grade lymphomas such as follicular lymphoma (n = 30), the local control rate was 100% regardless of dose. For 39 Stage I MALT lymphoma patients treated with radiation alone, the distant relapse-free survival rate was 75% at 5 years and 45% at 10 years. Distant relapses were generally isolated and successfully salvaged by local therapy. The overall survival for this subgroup was 81% at 10 years, with no deaths from lymphoma.
Conclusions:Dose-response data suggest that the optimal radiation dose for MALT lymphoma of the ocular adnexa is 30.6-32.4 Gy in 1.8-Gy fractions and follicular lymphoma is adequately controlled with doses in the mid-20 Gy range. The substantial risk of distant relapse in Stage I ocular adnexal MALT lymphoma underscores the importance of long-term follow-up for this disease and the need for additional comparative studies of MALT lymphoma of different anatomic sites.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/14630277
Author(s): Jaffe ES, Harris NL, Stein H, Vardiman JW
Author(s): Fitzpatrick PJ, Macko S
Author(s): Margo CE, Mulla ZD
Author(s): Dunbar SF, Linggood RM, Doppke KP
Author(s): Esik O, Ikeda H, Mukai K
Author(s): Smitt MC, Donaldson SS
Author(s): Stafford SL, Kozelsky TF, Garrity JA
Author(s): Lee SW, Suh CO, Kim GE
Author(s): Lee JL, Kim MK, Lee KH, Hyun MS, Chung HS, et al.
Author(s): Deeg HJ, Flournoy N, Sullivan KM
Author(s): Henk JM, Whitelocke RA, Warrington AP
Author(s): Suh CO, Shim SJ, Lee SW
Author(s): Goda JS, LeLW, Lapperriere NJ, Millar BA, Payne D, et al.
Author(s): Uno T, Isobe K, Shikama N
Author(s): Le QT, Eulau SM, George TI
Author(s): Tsang RW, Gospodarowicz MK, Pintilie M
Author(s): Husain A, Roberts D, Pro B, McLaughlin P, Esmaeli B